Vaxart Announces Positive Pre-Clinical Data for its Oral COVID-19 Vaccine Program
Vaxart, Inc. (VXRT)
Last vaxart, inc. earnings: 3/19 04:01 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
SOUTH SAN FRANCISCO, Calif., April 21, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that it has obtained positive pre-clinical results for its COVID-19 vaccine candidates, with several of the vaccine candidates generating immune responses in all tested animals after a single dose. “These early pre-clinical results are in line with those for our oral influenza vaccine which was protective in a clinical Phase 2 efficacy study,” said Sean Tucker, Ph.D., chief scientific officer of Vaxart. “Additional data will inform us on which candidate we will move forward into clinical trials. We are particularly interested in vaccine candidates that can generate mucosal immune responses in addition to serum antibody responses. That is a key feature of our oral vaccines and potentially significant for protection against SARS CoV-2, the virus that causes
Show less
Read more
Impact Snapshot
Event Time:
VXRT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VXRT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VXRT alerts
High impacting Vaxart, Inc. news events
Weekly update
A roundup of the hottest topics
VXRT
News
- Dr. Wouter Latour Joins PharmaJet as Chief Executive Officer [Yahoo! Finance]Yahoo! Finance
- Vaxart Announces Initiation of Sentinel Cohort for Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate [Yahoo! Finance]Yahoo! Finance
- C$ hits 6-day low on Powell remarks but posts quarterly gain [Yahoo! Finance Canada]Yahoo! Finance Canada
- Vaxart Announces Initiation of Sentinel Cohort for Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine CandidateGlobeNewswire
- Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
VXRT
Earnings
- 8/8/24 - Miss
VXRT
Sec Filings
- 10/8/24 - Form 424B5
- 10/8/24 - Form 8-K
- 9/30/24 - Form 8-K
- VXRT's page on the SEC website